SYMBIO - Growth Driver: PI3K Inhibitor’s Rigosertib & Cash to In-license More!
Disappointing guidance of TREAKISYM’s (bendamustine hydrochloride, L, rrNHL, MCL) sales for FY13 (¥1,927m de-growth of 1.4%) and discontinuation of TREAKISYM for refractory/relapsed aggressive non-Hodgkin’s Lymphoma (NHL) brought down SymBio pharma (4582, JP) stock from its 52 week high by ~40%. We remain optimistic on the future potential of its product portfolio- Label expansion of TREAKISYM, Rigosertib IV and Rigosertib Oral and cash for in-licensing other novel compounds. Data published in Lancet showed bendamustine/Rituximab Combo could become as a preferred 1st line treatment approach vs. R-CHOP…….For more details, please read our report released on 22nd February 2013 on SymBio titled “Growth Driver: PI3K Inhibitor’s Rigosertib & Cash to In-license More!”
